Is AZTR overvalued or undervalued?

AZTR currently has a P/E ratio of -0.10. Relative to the sector average of 23.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Azitra, Inc. stock?

Azitra, Inc. trades on AMEX. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of AZTR?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying AZTR protect my money against local inflation?

Many investors in Latin America buy international stocks like AZTR to protect their purchasing power. Because AZTR is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy AZTR shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is AZTR a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well AZTR diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksAZTR

Azitra, Inc.

$0.13-$0.00-1.59%

AMEX / USD

Market cap

$1M

P/E

-0.1

EPS (TTM)

$-0.64

Dividend yield

0.00%

Beta

-1.04

1Y return

-81.98%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$110,0002021

$284,0002022

$686,0002023

$7,5002024

$02025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.06Low
Current ratio4.86
Cash ratio4.40
Net margin0.0%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

AZTR-0.1
Healthcare sector median23.8
S&P 50022.0

Trades about 100% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.00
Price to book0.34
EPS (TTM)$-0.64
Payout ratio0%
FCF yield-8.84%

Range & risk

$0.10$1.09

Trading in the lower third of its 52-week band

Beta-1.04

Profile

What Azitra, Inc. actually does

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

CEO

Francisco D. Salva

Employees

Headquarters

Branford, CT

Founded

2023-06-20

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save AZTR and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

AZTR has a beta of -1.04, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Azitra, Inc.